JP2002516900A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002516900A5 JP2002516900A5 JP2000552085A JP2000552085A JP2002516900A5 JP 2002516900 A5 JP2002516900 A5 JP 2002516900A5 JP 2000552085 A JP2000552085 A JP 2000552085A JP 2000552085 A JP2000552085 A JP 2000552085A JP 2002516900 A5 JP2002516900 A5 JP 2002516900A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- solvate
- pharmaceutically acceptable
- preparing
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 29
- 239000012453 solvate Substances 0.000 claims 11
- 238000004519 manufacturing process Methods 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 239000011780 sodium chloride Substances 0.000 claims 9
- 230000002265 prevention Effects 0.000 claims 6
- 125000006239 protecting group Chemical group 0.000 claims 5
- 206010022489 Insulin resistance Diseases 0.000 claims 4
- 230000003301 hydrolyzing Effects 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 206010012601 Diabetes mellitus Diseases 0.000 claims 1
- 206010058108 Dyslipidaemia Diseases 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 206010061227 Lipid metabolism disease Diseases 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 230000001419 dependent Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Claims (15)
- 以下の式Ｉ：
- 請求項１に記載の化合物を調製する方法であって、以下の式ＩＩ：
の化合物を転換することを特徴とし、その後所望する場合は、得られた化合物を、医薬的に受容可能なその塩、及び／又は水和物のような溶媒和物に転換する方法。 - 請求項１に記載の化合物を調製する方法であって、以下の式ＩＩＩ：
の化合物と反応させ、その後必要な場合は、得られた化合物を加水分解することを特徴とし、その後所望する場合は、得られた化合物を、医薬的に受容可能なその塩、及び／又は水和物のような溶媒和物に転換する方法。 - 請求項１に記載の化合物を調製する方法であって、以下の式Ｖの化合物：
をジアステレオ異性体的に分離し、その後得られた化合物を加水分解することを特徴とし、その後所望する場合は、得られた化合物を、医薬的に受容可能なその塩、及び／又は水和物のような溶媒和物に転換する方法。 - 請求項１に記載の化合物を調製する方法であって、以下の式Ｖ：
の化合物を鏡像異性体的に分離し、その後必要な場合は、得られた化合物を加水分解することを特徴とし、その後所望する場合は、得られた化合物を、医薬的に受容可能なその塩、及び／又は水和物のような溶媒和物に転換する方法。 - 請求項１に記載の化合物を調製する方法であって、以下の式ＶＩＩ：
の化合物を不斉還元し、その後必要な場合は、得られた化合物を加水分解することを特徴とし、その後所望する場合は、得られた化合物を、医薬的に受容可能なその塩、及び／又は水和物のような溶媒和物に転換する方法。 - 請求項１に記載の化合物を調製する方法であって、以下の式ＸＩＩ：
の化合物をアルキル化し、その後必要な場合は、得られた化合物を加水分解することを特徴とし、その後所望する場合は、得られた化合物を、医薬的に受容可能なその塩、及び／又は水和物のような溶媒和物に転換する方法。 - 請求項１に記載の化合物を調製する方法であって、以下の式ＸＶ：
の化合物と反応させ、その後得られた化合物を加水分解することを特徴とし、その後所望する場合は、得られた化合物を、医薬的に受容可能なその塩、及び／又は水和物のような溶媒和物に転換する方法。 - 請求項１に記載の化合物を調製する方法であって、以下の式Ｉｒａｃ：
- 治療に使用するための、請求項１に記載の化合物。
- 有効成分として請求項１に記載の化合物を、所望により医薬的に受容可能な担体、賦形剤及び／又は希釈剤と共に含む、医薬製剤。
- インスリン抵抗性に伴なう臨床状態の予防及び／又は治療のための薬剤の製造における、請求項１に記載の化合物の使用。
- 前記インスリン抵抗性に伴なう臨床状態の予防及び／又は治療が、そのような状態の異常脂質血症（ｄｙｓｌｉｐｉｄａｅｍｉａ）の予防及び／又は治療である、請求項１２に記載の使用。
- 前記インスリン抵抗性に伴なう臨床状態の予防及び／又は治療が、インスリン非依存性糖尿病の高血糖症の予防及び／又は治療である、請求項１２に記載の使用。
- 有効成分が請求項１に記載の化合物である、インスリン抵抗性に伴なう臨床状態の予防及び／又は治療に使用するための医薬製剤。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9801992A SE9801992D0 (sv) | 1998-06-04 | 1998-06-04 | New 3-aryl-2-hydroxypropionic acid derivative I |
| SE9801992-0 | 1998-06-04 | ||
| PCT/SE1999/000941 WO1999062872A1 (en) | 1998-06-04 | 1999-05-31 | New 3-aryl-2-hydroxypropionic acid derivative (i) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003273428A Division JP2004043480A (ja) | 1998-06-04 | 2003-07-11 | 新規な３−アリール−２−ヒドロキシプロピオン酸誘導体ｉの中間体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002516900A JP2002516900A (ja) | 2002-06-11 |
| JP3554539B2 JP3554539B2 (ja) | 2004-08-18 |
| JP2002516900A5 true JP2002516900A5 (ja) | 2005-04-28 |
Family
ID=20411587
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000552085A Expired - Fee Related JP3554539B2 (ja) | 1998-06-04 | 1999-05-31 | 新規な３−アリール−２−ヒドロキシプロピオン酸誘導体ｉ |
| JP2003273428A Withdrawn JP2004043480A (ja) | 1998-06-04 | 2003-07-11 | 新規な３−アリール−２−ヒドロキシプロピオン酸誘導体ｉの中間体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003273428A Withdrawn JP2004043480A (ja) | 1998-06-04 | 2003-07-11 | 新規な３−アリール−２−ヒドロキシプロピオン酸誘導体ｉの中間体 |
Country Status (40)
| Country | Link |
|---|---|
| US (5) | US6258850B1 (ja) |
| EP (1) | EP1084103B1 (ja) |
| JP (2) | JP3554539B2 (ja) |
| KR (1) | KR100625152B1 (ja) |
| CN (2) | CN1311772A (ja) |
| AR (2) | AR020875A1 (ja) |
| AT (1) | ATE246674T1 (ja) |
| AU (1) | AU752261B2 (ja) |
| BR (1) | BR9910928A (ja) |
| CA (1) | CA2333938C (ja) |
| CZ (1) | CZ297424B6 (ja) |
| DE (1) | DE69910203T2 (ja) |
| DK (1) | DK1084103T3 (ja) |
| DZ (1) | DZ2800A1 (ja) |
| EE (1) | EE04772B1 (ja) |
| EG (1) | EG24140A (ja) |
| ES (1) | ES2205844T3 (ja) |
| HK (1) | HK1035711A1 (ja) |
| HR (1) | HRP20000782B1 (ja) |
| HU (1) | HUP0103376A3 (ja) |
| ID (1) | ID28833A (ja) |
| IL (1) | IL139636A (ja) |
| IS (1) | IS2071B (ja) |
| MA (1) | MA26635A1 (ja) |
| MY (1) | MY117785A (ja) |
| NO (1) | NO323426B1 (ja) |
| NZ (1) | NZ508452A (ja) |
| PL (1) | PL195189B1 (ja) |
| PT (1) | PT1084103E (ja) |
| RS (1) | RS49688B (ja) |
| RU (1) | RU2214999C2 (ja) |
| SA (1) | SA99200304B1 (ja) |
| SE (1) | SE9801992D0 (ja) |
| SK (1) | SK284642B6 (ja) |
| TN (1) | TNSN99108A1 (ja) |
| TR (1) | TR200003581T2 (ja) |
| TW (1) | TW446696B (ja) |
| UA (1) | UA71912C2 (ja) |
| WO (1) | WO1999062872A1 (ja) |
| ZA (1) | ZA200006774B (ja) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8702758D0 (en) * | 1987-02-06 | 1987-03-11 | Wellcome Found | Treatment of disease |
| ATE304864T1 (de) | 1997-01-07 | 2005-10-15 | Amylin Pharmaceuticals Inc | Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme |
| US6130214A (en) * | 1997-10-27 | 2000-10-10 | Dr. Reddy's Research Foundation | Benzothiazin and benzoxazin derivatives; their preparation and uses |
| SE9801992D0 (sv) * | 1998-06-04 | 1998-06-04 | Astra Ab | New 3-aryl-2-hydroxypropionic acid derivative I |
| MA26634A1 (fr) | 1998-06-04 | 2004-12-20 | Astra Ab | Nouveaux derives de l'acide 3-aryl propionique et analogues |
| SE9904421D0 (sv) | 1999-12-03 | 1999-12-03 | Astra Ab | New compounds |
| EE200200278A (et) * | 1999-12-03 | 2003-06-16 | Astrazeneca Ab | (S)-2-etoksü-3-[4-(2-{4-metaansulfonüüloksüfenüül}etoksü)fenüül]propaanhappe kristalne vorm |
| US7084177B2 (en) * | 1999-12-03 | 2006-08-01 | Astrazeneca Ab | Comminuted form of(S)-2-ethoxy-3-[4-(2-{4-methanesulfonyloxyphenyl}ethoxy)phenyl] propanoic acid |
| SE9904415D0 (sv) * | 1999-12-03 | 1999-12-03 | Astra Ab | New process |
| TW574193B (en) * | 1999-12-03 | 2004-02-01 | Astrazeneca Ab | Novel phenalkyloxy-phenyl derivatives, pharmaceutical composition containing the same and their uses |
| PT1246638E (pt) * | 2000-01-10 | 2004-12-31 | Amylin Pharmaceuticals Inc | Utilizacao de exendinas e seus agonistas para o tratamento da ipertrigliceridemia |
| US6559335B2 (en) | 2000-09-22 | 2003-05-06 | Dr. Reddy's Laboratories Limited | Process for the preparation of 3-aryl-2-hydroxy propanoic acid |
| WO2002051441A1 (fr) | 2000-12-26 | 2002-07-04 | Sankyo Company, Limited | Compositions medicinales contenant un diuretique et un agent renforçant la resistance a l'insuline |
| SE0101386D0 (sv) | 2001-04-20 | 2001-04-20 | Astrazeneca Ab | New compounds |
| WO2002096865A1 (en) * | 2001-06-01 | 2002-12-05 | Astrazeneca Ab | Process for the preparation 3-aryl-2-hydroxypropionic acid derivative |
| SE0101980D0 (sv) * | 2001-06-01 | 2001-06-01 | Astrazeneca Ab | Pharmaceutical combination |
| SE0101981D0 (sv) * | 2001-06-01 | 2001-06-01 | Astrazeneca Ab | Pharmaceutical combination |
| SE0101978D0 (sv) | 2001-06-01 | 2001-06-01 | Astrazeneca Ab | New compounds |
| SE0101982D0 (sv) * | 2001-06-01 | 2001-06-01 | Astrazeneca Ab | Pharmaceutical combination |
| BR0210190A (pt) | 2001-06-07 | 2004-04-06 | Lilly Co Eli | Moduladores de receptores ativados de proliferador de peroxissomo |
| EP1461323B1 (en) * | 2001-06-12 | 2013-10-09 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| UA82835C2 (en) | 2001-12-03 | 2008-05-26 | Reddys Lab Ltd Dr | ?-aryl-?-oxysubstituted propionuc acid derivatives and pharmaceutical composition based thereon |
| GB0314079D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0229931D0 (en) * | 2002-12-21 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
| SE0104334D0 (sv) * | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| SE0104333D0 (sv) * | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| AU2002351752A1 (en) | 2001-12-29 | 2003-07-30 | Novo Nordisk A/S | Combined use of a glp-1 compound and another drug for treating dyslipidemia |
| SE0201005D0 (sv) * | 2002-04-02 | 2002-04-02 | Astrazeneca Ab | New Process |
| US20050119314A1 (en) * | 2002-04-05 | 2005-06-02 | Sankyo Company, Limited | Pharmaceutical composition comprising an ACAT inhibitor and an insulin resistance reducing agent |
| US7351858B2 (en) * | 2002-06-20 | 2008-04-01 | Astrazeneca Ab | Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance |
| SE0201937D0 (sv) * | 2002-06-20 | 2002-06-20 | Astrazeneca Ab | Therapeutic agents |
| WO2004000790A1 (en) * | 2002-06-20 | 2003-12-31 | Astrazeneca Ab | Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance |
| SE0201936D0 (sv) * | 2002-06-20 | 2002-06-20 | Astrazeneca Ab | Therapeutic agents |
| DE10308351A1 (de) | 2003-02-27 | 2004-11-25 | Aventis Pharma Deutschland Gmbh | 1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE10308355A1 (de) | 2003-02-27 | 2004-12-23 | Aventis Pharma Deutschland Gmbh | Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel |
| US7148246B2 (en) | 2003-02-27 | 2006-12-12 | Sanofi-Aventis Deutschland Gmbh | Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals |
| DE10308353A1 (de) | 2003-02-27 | 2004-12-02 | Aventis Pharma Deutschland Gmbh | Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE10308352A1 (de) | 2003-02-27 | 2004-09-09 | Aventis Pharma Deutschland Gmbh | Arylcycloalkylderivate mit verzweigten Seitenketten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel |
| AU2004266204A1 (en) * | 2003-06-06 | 2005-03-03 | Cadila Healthcare Limited | Process for preparing 3-aryl-2-hydroxy propanoic acid derivatives without resolution |
| GB0314130D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0314078D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0314131D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0314075D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0314260D0 (en) | 2003-06-19 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| US7829552B2 (en) | 2003-11-19 | 2010-11-09 | Metabasis Therapeutics, Inc. | Phosphorus-containing thyromimetics |
| US20070142472A1 (en) * | 2003-11-27 | 2007-06-21 | Tohru Yokozawa | Process for producing optically active 3-(4-hydroxyphenyl)proprionic acids |
| DE602004004631D1 (de) | 2004-04-01 | 2007-03-22 | Sanofi Aventis Deutschland | Oxadiazolone, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Pharmazeutika |
| JP4177435B2 (ja) | 2004-04-03 | 2008-11-05 | アストラゼネカ アクチボラグ | 治療薬 |
| FR2872159B1 (fr) * | 2004-06-28 | 2007-10-05 | Merck Sante Soc Par Actions Si | Nouveaux derives acides carboxyliques phenyliques et leur utilisation dans le traitement du diabete |
| TW200608967A (en) | 2004-07-29 | 2006-03-16 | Sankyo Co | Pharmaceutical compositions containing with diabetic agent |
| CN102600144A (zh) * | 2005-03-08 | 2012-07-25 | 奈科明有限责任公司 | 治疗糖尿病的罗氟司特 |
| DE102005026762A1 (de) | 2005-06-09 | 2006-12-21 | Sanofi-Aventis Deutschland Gmbh | Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen |
| AU2007274598A1 (en) * | 2006-07-21 | 2008-01-24 | Lupin Limited | Antidiabetic azabicyclo [3. 1. 0] hexan compounds |
| KR100958831B1 (ko) * | 2006-09-19 | 2010-05-24 | 주식회사유한양행 | 헤테로아릴피리미딘 유도체, 이들의 제조방법, 및 이들을포함하는 조성물 |
| US20090082441A1 (en) * | 2007-09-25 | 2009-03-26 | Protia, Llc | Deuterium-enriched tesaglitazar |
| US20120046364A1 (en) | 2009-02-10 | 2012-02-23 | Metabasis Therapeutics, Inc. | Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use |
| PL2637646T3 (pl) | 2010-11-08 | 2017-01-31 | Albireo Ab | Kombinacja farmaceutyczna zawierająca inhibitor ibat i środek wiążący kwasy żółciowe |
| DK3400944T3 (da) | 2010-11-08 | 2020-10-12 | Albireo Ab | Ibat-inhibitorer til behandling af leversygdomme |
| EP2758041B1 (de) | 2011-09-20 | 2021-01-13 | Basf Se | Niedermolekulare modulatoren des kälte-menthol-rezeptors trpm8 und deren verwendung |
| WO2014155291A1 (en) * | 2013-03-27 | 2014-10-02 | Pfizer Ireland Pharmaceuticals | Process and intermediates for the preparation of pregabalin |
| MX2016000724A (es) * | 2013-07-22 | 2016-04-13 | Metabolic Solutions Dev Co Llc | Compuestos de reserva de los receptores activados del proliferador de peroxisoma (ppar) para el tratamiento de enfermedades metabolicas. |
| WO2024100051A1 (en) | 2022-11-08 | 2024-05-16 | Genfit | Ppar-alpha/gamma agonist for use in the treatment of liver failure |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4114417A (en) * | 1977-06-27 | 1978-09-19 | Schmelzer Corporation | Method and apparatus for making metal parts |
| US4479005A (en) * | 1982-12-16 | 1984-10-23 | The Dow Chemical Company | Selective preparation of isomers and enantiomers of cyclopropane carboxylic acids |
| FR2653119B1 (fr) | 1989-10-18 | 1994-08-05 | Lipha | Nouveaux aryloxy alcoyl benzenes, leurs procedes de preparation et les compositions pharmaceutiques en renfermant. |
| US5068345A (en) * | 1989-10-30 | 1991-11-26 | Eastman Kodak Company | Oxazolidinone aldol adduct |
| US5089514A (en) | 1990-06-14 | 1992-02-18 | Pfizer Inc. | 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents |
| GB9114948D0 (en) * | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| EP0648212B1 (en) * | 1992-07-03 | 2001-10-24 | Smithkline Beecham Plc | Benzoxazole and benzothiazole derivatives as pharmaceutical |
| US5232945A (en) | 1992-07-20 | 1993-08-03 | Pfizer Inc. | 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives |
| US5648541A (en) * | 1995-09-28 | 1997-07-15 | Nps Pharmaceuticals, Inc. | Chiral reductions of imines leading to the syntheses of optically active amines |
| GB9604242D0 (en) * | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
| NZ332136A (en) * | 1996-04-04 | 1999-08-30 | Sankyo Co | Phenylalkylcarboxylic acid derivatives useful for treating hyperglycemia |
| PL193086B1 (pl) * | 1997-10-27 | 2007-01-31 | Reddys Lab Ltd Dr | Nowe związki tricykliczne i związki pośrednie, sposób ich wytwarzania, zawierające je kompozycje farmaceutyczne oraz ich zastosowanie |
| MA26634A1 (fr) * | 1998-06-04 | 2004-12-20 | Astra Ab | Nouveaux derives de l'acide 3-aryl propionique et analogues |
| SE9801990D0 (sv) * | 1998-06-04 | 1998-06-04 | Astra Ab | New 3-aryl propionic acid derivatives and analogs |
| SE9801992D0 (sv) * | 1998-06-04 | 1998-06-04 | Astra Ab | New 3-aryl-2-hydroxypropionic acid derivative I |
-
1998
- 1998-06-04 SE SE9801992A patent/SE9801992D0/xx unknown
-
1999
- 1999-05-20 MA MA25592A patent/MA26635A1/fr unknown
- 1999-05-23 DZ DZ990100A patent/DZ2800A1/xx active
- 1999-05-25 TW TW088108576A patent/TW446696B/zh not_active IP Right Cessation
- 1999-05-31 ID IDW20002652A patent/ID28833A/id unknown
- 1999-05-31 UA UA2000116621A patent/UA71912C2/uk unknown
- 1999-05-31 ES ES99930059T patent/ES2205844T3/es not_active Expired - Lifetime
- 1999-05-31 HU HU0103376A patent/HUP0103376A3/hu unknown
- 1999-05-31 PL PL99345205A patent/PL195189B1/pl not_active IP Right Cessation
- 1999-05-31 AU AU46671/99A patent/AU752261B2/en not_active Ceased
- 1999-05-31 CA CA002333938A patent/CA2333938C/en not_active Expired - Fee Related
- 1999-05-31 WO PCT/SE1999/000941 patent/WO1999062872A1/en active IP Right Grant
- 1999-05-31 DE DE69910203T patent/DE69910203T2/de not_active Expired - Fee Related
- 1999-05-31 BR BR9910928-0A patent/BR9910928A/pt not_active Application Discontinuation
- 1999-05-31 US US09/341,904 patent/US6258850B1/en not_active Expired - Fee Related
- 1999-05-31 EP EP99930059A patent/EP1084103B1/en not_active Expired - Lifetime
- 1999-05-31 JP JP2000552085A patent/JP3554539B2/ja not_active Expired - Fee Related
- 1999-05-31 AT AT99930059T patent/ATE246674T1/de not_active IP Right Cessation
- 1999-05-31 TR TR2000/03581T patent/TR200003581T2/xx unknown
- 1999-05-31 CZ CZ20004484A patent/CZ297424B6/cs not_active IP Right Cessation
- 1999-05-31 SK SK1768-2000A patent/SK284642B6/sk not_active IP Right Cessation
- 1999-05-31 DK DK99930059T patent/DK1084103T3/da active
- 1999-05-31 CN CN99809340A patent/CN1311772A/zh active Pending
- 1999-05-31 RU RU2000130189/04A patent/RU2214999C2/ru not_active IP Right Cessation
- 1999-05-31 NZ NZ508452A patent/NZ508452A/en unknown
- 1999-05-31 KR KR1020007013662A patent/KR100625152B1/ko not_active IP Right Cessation
- 1999-05-31 RS YUP-745/00A patent/RS49688B/sr unknown
- 1999-05-31 CN CNB2005100687433A patent/CN1310881C/zh not_active Expired - Fee Related
- 1999-05-31 PT PT99930059T patent/PT1084103E/pt unknown
- 1999-05-31 EE EEP200000720A patent/EE04772B1/xx not_active IP Right Cessation
- 1999-05-31 IL IL13963699A patent/IL139636A/xx not_active IP Right Cessation
- 1999-06-02 TN TNTNSN99108A patent/TNSN99108A1/fr unknown
- 1999-06-02 MY MYPI99002209A patent/MY117785A/en unknown
- 1999-06-03 EG EG65699A patent/EG24140A/xx active
- 1999-06-03 AR ARP990102635A patent/AR020875A1/es active IP Right Grant
- 1999-06-28 SA SA99200304A patent/SA99200304B1/ar unknown
-
2000
- 2000-05-22 AR ARP000102487A patent/AR024061A2/es unknown
- 2000-11-16 HR HR20000782A patent/HRP20000782B1/xx not_active IP Right Cessation
- 2000-11-17 IS IS5714A patent/IS2071B/is unknown
- 2000-11-20 ZA ZA200006774A patent/ZA200006774B/en unknown
- 2000-12-01 NO NO20006115A patent/NO323426B1/no unknown
-
2001
- 2001-05-18 US US09/861,163 patent/US20010034371A1/en not_active Abandoned
- 2001-08-17 HK HK01105811A patent/HK1035711A1/xx not_active IP Right Cessation
-
2002
- 2002-01-04 US US10/039,868 patent/US6660879B2/en not_active Expired - Fee Related
-
2003
- 2003-07-11 JP JP2003273428A patent/JP2004043480A/ja not_active Withdrawn
- 2003-09-22 US US10/669,131 patent/US20040229946A1/en not_active Abandoned
-
2005
- 2005-03-11 US US11/078,201 patent/US20060040979A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002516900A5 (ja) | ||
| RU2214999C2 (ru) | Производное 3-арил-2-гидроксипропионовой кислоты, способ его получения(варианты), фармацевтический препарат, способ лечения и промежуточный продукт | |
| RU2000130189A (ru) | Новое производное i 3-арил-2-гидроксипропионовой кислоты | |
| EP0668851B1 (en) | A novel arylpropionic derivative, a process for the preparation and the use thereof as an analgesic agent | |
| JP2002508375A5 (ja) | ||
| CS208664B2 (en) | Method of making the new r,s-n-/2-phenyl-2-hydroxyethyl/-1-alkyl-3-/4-substituted phenyl/propylamines | |
| TW200920374A (en) | Rosuvastatin calcium in solid state, pharmaceutical composition comprising the same, and use thereof | |
| JP2002513793A5 (ja) | ||
| JP2009143954A (ja) | チアゾリジンジオン誘導体および抗糖尿病薬としてのその使用 | |
| JP2002543077A (ja) | ５−［４−［２−（ｎ−メチル−ｎ−（２−ピリジル）アミノ）エトキシ］ベンジル］チアゾリジン−２，４−ジオン，マレイン酸塩の多形体 | |
| JP2009161544A (ja) | チアゾリジンジオン誘導体および抗糖尿病薬としてのその使用 | |
| JP6246589B2 (ja) | ナルトレキソンの製造方法 | |
| JP2005513014A5 (ja) | ||
| US6939856B2 (en) | Method for preparing dexchlor tannate | |
| JPH0725724B2 (ja) | トラネキサム酸亜鉛化合物 | |
| CA1172170A (en) | Antiviral alpha, alpha-dialkyl adamantylethylamines | |
| RU2004124840A (ru) | Твердые соли бензазепиновых соединений и их применение при получении фармацевтических соединений | |
| JP2003519683A5 (ja) | ||
| EP0030023A3 (en) | A heterocyclic compound and its synthesis, pharmaceutical formulations thereof and the use of the compounds and the formulations in medicine | |
| JP2002536442A5 (ja) | ||
| JPH033671B2 (ja) | ||
| JP2003520835A5 (ja) | ||
| EP0246888A3 (en) | Dopamine-beta-hydroxylase inhibitors | |
| CN1080851A (zh) | 生长激素释放抑制因子的增强剂 | |
| JPH0225468A (ja) | イミダゾール誘導体及びその製造方法 |